Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Anand V R Kornepati"'
Autor:
Tyler Curiel, Yilun Deng, Aravind Kancharla, Myrna Garcia, Haiyan Bai, Ryan Michael Reyes, Harshita B Gupta, Alvaro S Padron, Anand V R Kornepati, Jose R Conejo-Garcia, Yiji J Liao, Clare J Murray, Carlos Ontiveros, Suresh J Kari
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background Tumor intracellular programmed cell death ligand-1 (PDL1) mediates pathologic signals that regulate clinical treatment responses distinctly from surface-expressed PDL1 targeted by αPDL1 immune checkpoint blockade antibodies.Methods We per
Externí odkaz:
https://doaj.org/article/17e6b1fa8654420fb479e0007b231c94
Autor:
Yilun Deng, Aravind Kancharla, Myrna Garcia, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Tyler J Curiel, Robert S Svatek, Ryan Michael Reyes, Harshita B Gupta, Alvaro S Padron, Chenghao Zhang, Anand V R Kornepati, Onur Boyman, Jose R Conejo-Garcia
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background Anti-programmed death-ligand 1 (αPD-L1) immunotherapy is approved to treat bladder cancer (BC) but is effective in
Externí odkaz:
https://doaj.org/article/2a231be16e8747f5b3befb1e7bde6cde
Publikováno v:
Nat Rev Cancer
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to develop effective and revolutionary immunotherapies using antibodies blocking these cel
Autor:
Haiyan Bai, Alvaro S Padron, Yilun Deng, Yiji J Liao, Clare J Murray, Carlos Ontiveros, Suresh J Kari, Aravind Kancharla, Anand V R Kornepati, Myrna Garcia, Ryan Michael Reyes, Harshita B Gupta, Jose R Conejo-Garcia, Tyler Curiel
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e004871
BackgroundTumor intracellular programmed cell death ligand-1 (PDL1) mediates pathologic signals that regulate clinical treatment responses distinctly from surface-expressed PDL1 targeted by αPDL1 immune checkpoint blockade antibodies.MethodsWe perfo
Publikováno v:
Nature reviews. Cancer. 22(3)
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to develop effective and revolutionary immunotherapies using antibodies blocking these cel
Publikováno v:
Nature Reviews Cancer. 22:190-190
Autor:
Deyi Zhang, Ryan M. Reyes, Erica Osta, Suresh Kari, Harshita B. Gupta, Alvaro S. Padron, Anand V. R. Kornepati, Aravind Kancharla, Xiujie Sun, Yilun Deng, Bogang Wu, Ratna Vadlamudi, Rong Li, Robert S. Svatek, Tyler J. Curiel
Publikováno v:
Cancer Medicine, Vol 10, Iss 6, Pp 2137-2152 (2021)
Abstract Tumor cell‐intrinsic programmed death‐ligand 1 (PD‐L1) signals mediate immunopathologic effects in breast, colon, and ovarian cancers and in melanomas, but bladder cancer (BC) effects are unreported. We show here that BC cell‐intrins
Externí odkaz:
https://doaj.org/article/e4a5d1a873db407eb7004100b7129f12